1. Cholesteryl Ester Transfer Protein Inhibitors

2. Learning Objectives

3. Benefits of Statins on Major Vascular Events

6. IMPROVE-IT Benefit of Adding the Non-statin Ezetimibe to Statin Therapy

7. HDL-C and CHD Risk Epidemiologic Observations

8. Reverse Cholesterol Transport

9. Reverse Cholesterol Transport and CETP inhibition

10. Bad Few Years for HDL-C

11. ILLUMINATE Torcetrapib in Patients at High Risk for Coronary Events

12. ILLUMINATE Torcetrapib in Patients at High Risk for Coronary Events

14. dal-OUTCOMES Dalcetrapib in Patients With Recent ACS

15. dal-OUTCOMES Dalcetrapib Did Not Reduce Risk of Recurrent CV Events

17. Copenhagen City Heart Study Genetic Inhibition of CETP

18. Reverse Cholesterol Transport Animal Model

19. Functionality of Accumulating HDL After Niacin or Anacetrapib Treatment

20. Novel CETP Inhibitor K-312 Suppresses PCSK9 Expression

21. Lipid Effects of CETP Inhibitors Summary

22. Estimation of LDL-C Concentration

23. Anacetrapib Pharmacokinetics

24. DEFINE Safety of Anacetrapib in Patients With/at High Risk for CHD

25. DEFINE Cardiac Events

26. REVEAL Anacetrapib in Patients With Occlusive Arterial Disease

27. Evacetrapib Phase 2 Trial Monotherapy or With Statins

28. Evacetrapib Monotherapy Lipid Changes

29. Evacetrapib + Statin Therapy HDL-C Changes

30. Evacetrapib + Statin Therapy LDL-C Changes

31. Evacetrapib Safety

33. CETP Inhibitors Will They Work?

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)

37. References

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)